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Comparative study of an angiotensin-Il analog and a converting
enzyme inhibitor. The effects of an angiotensin-Il analog (sarala-
sin, iv.) and of a converting enzyme inhibitor (captopril, oral)
were compared in 12 sodium-depleted patients with hyper-
tension. The decrease of the mean intraarterial pressure (MAP)
with captopril (—21.5 [sEM] 4.3 mm Hg) was more pronounced
(P < 0.001) than the change of MAP during saralasin (—10.5
4.0 mm Hg). The pretreatment arterial plasma renin activity (log
PRA) was closely related to the change of MAP during saralasin
(r =
—0.94; P < 0.001) and also to the captopril-induced change
of MAP(r —0.82; P <0.001); similar results were obtained for
the log plasma angiotensin (PA) I and II levels. The change of
MAP was more pronounced, however, with captopril than dur-
ing saralasin at any level of pretreatment PRA, PAL or PAIL. Sa-
ralasin did not affect heart rate (P> 0.4), but during captopril the
heart rate increased by 5.1 beats/mm (P < 0.001). Captopril pro-
duced a 70% decrease of PAIl, but the change of MAP was poorly
related to the changes of PAIL (r = —0.57; P < 0.05); PRA and PAL
rose threefold to fourfold. PRA, PAL, and PALL all increased during
saralasin. These observations may suggest that the anti-
hypertensive action of captopril is not based solely on the inhibi-
tion of All formation, but also the agonistic effect of saralasin
has to be considered.
Etude comparative d'un analogue de l'angiotensine II et d'un
inhibiteur de l'enzyme de conversion. Les effets d'un analogue de
l'angiotensine II (saralasine, i.v.) et d'un inhibiteur de l'enzyme
de conversion (captopril, oral) ont &é compares chez 12 malades
atteints d'hypertension et déplétés en sodium. La diminution de
Ia pression intra-artérielle moyenne (MAP) avec Ic captopril
(—21,5 [5EM] 4,3 mm Hg) a été plus prononcCe (P < 0,001) que
Ia modification de MAP avec Ia saralasine (— 10,5 4,0mm Hg).
L'activité rdnine plasmatique avant traitement (log PRA) était
étroitement liCe a Ia modification de MAP au cours du traitement
par Ia saralasine (r =
—0,94; P < 0,001) et aussi a Ia modifica-
tion de MAP déterminCe par le captopril (r = —0.82; P < 0,001);
des rCsultats semblables ont Cte obtenus pour des concentra-
tions plasmatiques d'angiotensine (PA) I et II. Cependant, Ia
modification de MAP Ctait plus importante avec le captopril
qu'avec Ia saralasine a tous les niveaux de PRA, PAL, ou PALL
avant traitement. La saralasine n'a pas affectC le rythme car-
diaque (P < 0,4), mais le captopril I'a augmentd de 5,1 batte-
ments minute (P < 0,001). Le captopnl a produit une diminution
de 70% de PAIL, mais Ia modification de MAP Ctait faiblement liCe
aux modifications de PAIL (r =
—0,57; P < 0,05); PRA et PAL ont
etC multipliees par 3 a 4. PRA, PAL, et PAIL ont augmentd au cours
de l'administration de saralasine. Ces observations peuvent sug-
gérer que I'action antihypertensive du captopril n'est pas seule-
ment fondde sur l'inhibition de Ia formation d'AII, mais que
l'effet agoniste de Ia saralasine doit aussi Ctre considérC.
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The angiotensin-Il (All) analog sar1 ala8-angioten-
sin II, a specific antagonist of the vascular effects of
All [1], has been studied intensively in patients with
hypertension, and is a powerful hypotensive agent
in sodium-volume-depleted hypertensive patients
except in patients with low plasma renin values. Its
effect to lower blood pressure is indeed closely re-
lated to the plasma levels of renin or All [2-5], and
blood pressure normalizes in about two thirds of the
patients with hypertension of various etiologies
when treated with chlorthalidone and saralasin [4]
(P113, sar1ala8-angiotensin II, Norwich Pharma-
cal Co.). The use of saralasin is limited, however,
because it requires parenteral administration. At
present, no orally active antagonist of All is avail-
able. Also, converting enzyme inhibition with the
nonapeptide SQ 20881, which blocks the con-
version of Al to All, requires parenteral administra-
tion, but recently an orally active compound
(SQ 14225, captopril; 2-D-methyl-3 mercaptopro-
panoyl-L-proline; Squibb Institute for Medical Re-
search) has been synthesized [6].
Both ways of interference with the renin angio-
tensin system have been used to lower blood pres-
sure and to study the pathophysiologic role of the
system in hypertension [2—5, 7—10]. In the present
study, we compare the effects of saralasin and cap-
topril on blood pressure in patients with moderate
to severe essential or renovascular hypertension.
Methods
Twelve patients with hypertension of various
etiologies were studied. Informed consent was ob-
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tamed before admission into the study. Their char-
acteristics are given in Table 1. Their diagnoses
were based on history, physical examination, ap-
propriate laboratory tests, intravenous pyelogram,
and renal arteriogram, if indicated; the severity of
hypertension was assessed by the criteria of the
World Health Organisation (the one patient with
stage 3 had a grade-3 eye fundus). In the patients
with renal artery stenosis (all 60%), blood for de-
termination of plasma renin activity (PRA) was
sampled from both renal veins and from the femoral
artery. The ratio of PRA in the renal vein of the
affected side to the arterial PRA was > 2.0 in five
patients and < 1.5 in one.
After the described investigations, all patients
were started on three placebo tablets a day and
were instructed to observe a low sodium diet; four
patients were also treated with chlorthalidone, 50
mg/day. Patients were followed on an outpatient
basis for about I month, except for two patients in
whom it was considered unethical because of the
severity of hypertension. Urinary sodium excretion
during the 24 hours prior to the present study aver-
aged 26.3 (sEM) 7.6 mmoles.
The saralasin infusion test and the administration
of the first dose of captopril were performed in the
recumbent patient, in the morning, after a light
breakfast, in the laboratory where the room temper-
ature was 18° to 22° C and the humidity was 40 to
60%. A small catheter (Vygon, 115.09) was in-
troduced in the brachial artery for sampling of blood
and for recording the intraarterial pressure with a
pressure transducer (Elema Schonander EMT).
Pressure was continuously recorded on a recorder
(Mingograph 81), and mean arterial pressure (MAP)
was obtained by electrical damping every 5 mm.
Heart rate (HR) was calculated from the elec-
trocardiogram (ECG). After the technical proce-
dures, including insertion of a needle into an arm
vein, a control period of 30 mm was observed while
glucose 5% was given i.v. Then, saralasin was in-
fused at a rate of 10 gfkg/min for 45 mm. After
interruption of the drug infusion, a wash-out period
of 90 mm was observed. Then the patient received I
tablet of captopril, 25 mg, and blood pressure and
heart rate were followed for another 75 mm.
Arterial blood was drawn prior to and at the end
of the saralasin infusion and also before the capto-
pril administration and at the end of the observation
period. The PRA was determined by the method of
Vallotton [11]. The measurements of circulating
plasma Al (PAl) [12] and of All (PAll) [13] have been
described. The crossreactivity of A! and of sarala-
sin with the All antibody has been tested and was
found to be extremely low, namely 0.33% and
0.0025%, respectively. Plasma converting enzyme
activity (PACE) was measured according to Lijnen
et al [14].
Statistical methods used are the regression analy-
sis and Student's two tailed t test for paired data.
The dispersion of the data is given by standard error
of the mean (sEM). Biochemical variables (except
PACE) were transformed to their logarithms be-
cause only their log distribution was Gaussian.
Results
Effects of saralasin and captopril on PRA, PAl,
PA/I, and PACE. Table 2 shows the results for log-
transformed PRA, PA!, and PAL! before and during
both saralasin and captopril treatment. The antilog
of the mean values of log PRA, log PA!, and log PAIL
is also given. Saralasin produced significant twofold
to threefold increases of PRA, PAl, and of PAIL lev-
els, whereas PACE was not affected. PAIL dropped
significantly during captopril. Figure 1 illustrates
the time-course of the changes in PAIl in eight pa-
tients in whom it was measured at several intervals;
PAIL was reduced to about 50% at 30 mm and de-
creased further to a level of 28% after 75 mm. PRA
and PAL increased about threefold to fourfold, but
PACE decreased by 45%.
Effects of saralasin and captopril on arterial
pressure and heart rate. The time-course of the
changes of mean arterial pressure (MAP) during
treatment with i.v. saralasin and oral captopril is
shown in Fig. 2. After an initial transient increase
by 10.6 2.8 mm Hg (P < 0.005) during the sarala-
sin infusion, pressure dropped and reached plateau
levels after about 30 mm; MAP during the last 5 mm
(119.7 5.2) was significantly (P < 0.03) different
Table 1. Characteristics of patients
Sex: males/females, N
Age, yr
Weight, kg
Stage WHO
1,N
2,N
3,N
Intra-arterial pressure at the end
of control period:
Systolic, mm Hg
Diastolic, mm Hg
Mean, mm Hg
Creatinine clearance, ml/mi,i
Etiology of hypertension
Essential, N
Renal artery stenosis, N
8/4
39.9 3.l
71.0 2.7a
6
5
180.3 l1.3a
99.0 7.2
130.2 8.0
89.4 l0.7a
6
6
Values are means SEM.
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from the 5-mm preinfusion control value (130.2
8.0 mm Hg). MAP had regained control values 90
mm after interruption of saralasin (130.7 7.2 mm
Hg). With 25 mg of oral captopril, MAP decreased
steadily. After 45 mm, MAP was significantly (P <
0.01) lower than MAP at the end of the 45-mm sa-
ralasin infusion. MAP plateaued after 50 mm and
reached a value of 109.3 4.1 mm Hg at the end of
the observation period (P <0.001 when compared
to control). The final captopril-induced decrease of
MAP was more pronounced than the change in
MAP during saralasin infusion in all instances, but
the pressure responses to both drugs were closely
related (MAP5 = —11.6 + 0.94 LMAPsar r =
+0.88; P < 0.001).
Heart rate was not affected by saralasin (P> 0.4)
except for an initial transient slowing by 6.8 1.7
beats/mm (P < 0.005), which parallelled the pres-
sure increase (Fig. 2). With captopril, HR increased
from a control level of 79.2 3.0 to 84.3 3.4
beats/mm (P < 0.001) at the end of the observation
period; already after 20 mm, when the changes of
MAP were similar to the changes during saralasin,
HR had increased by 5.6 1.8 beats/mm (P < 0.01)
in response to captopril, but it was not affected by
saralasin (P> 0.6).
Relationship of the change of mean arterial pres-
sure to PRA, PA!, and PA1,. The change of MAP dur-
ing saralasin was closely related to log PRA ob-
tained prior to its infusion (MAP5ar = —2.5 —20.5
log PRA; r = —0.94; P < 0.001). Also, the captopril-
induced changes of MAP were significantly related
to log PRA before its ingestion (zMAPcap = 11.7
— 18.4 log PRA; r = —0.82; P < 0.001). The change
30 45 60 75
Time, mm
Fig. 1. Plasma angiotensin II at several intervals after captopril
administration, expressed in percentage of initial PA!!. Values
are the means SaM.
in MAP was more pronounced, however, with cap-
topril than it was during saralasin at any level of
PRA (fig. 3); the slope of both regression equations
was similar (P > 0.1), but the intercept was signifi-
cantly different (P < 0.005). Similar results were ob-
tained when the hypotensive effect of saralasin and
captopnl were compared with the preexisting log
PA!! values (MAPsar = 33.9 — 27.9 log PA!!; r =
—0.74;P< 0.01; MAPcap = 26.1 — 28.6 log PA!!; r
= —0.72; P < 0.01) or log PA! levels (zMAPsar =
40.6 — 23.8 log PA!; r = —0.91; P < 0.001; LMAPcap
Table 2. Plasma renin activity (PRA), plasma angiotensin land II (PA! and PAIl), and plasma converting enzyme activity (PACE) before
and during saralasin and captopril
Saralasin Captopril
Before During Pb Before During P'
PRA
Range, nglml/hr 0.56 to 24.8 1.47 to 123.2 0.64 to 28.0 1.02 to 97.6
MeanoflogPRAa,/ogng/ml/hr 0.31 0.18 0.67 0.25 <0.005 0.35 0.21 0.91 0.22 <0.001
Antilogofmean,nglml/hr 2.04 4.68 2.24 8.13
PAl
Range,pglml 41.7to 1364 59to6331 39.lto 1418 72.5to6328
Mean of log P!',log pg/mi 2.19 0.16 2.63 0.22 <0.005 2.22 0.17 2.82 0.19 <0.001
Antilog of mean,pglml 156 431 167 666
PA!!
Range,pg/mi l2.9to 175 15.3 to650 15.3 to 233 4.9to40.9
Mfl of log log pg/mi 1.61 0.11 1.96 0.18 <0.005 1.66 0.11 1.21 0.10 <0.001
Antilogofmean,pg/ml 41.0 90.6 45.6 16.3
PACE
Range, U/mI 11.0 to 45.1 10.4 to 52.0 10.2 to 56.4 7.0 to 35.6
Mean PACEa, U/mI 32.3 2.8 32.4 3.2 NS 32.7 3.2 18.1 2.7 <0.001
a Values are the means SEM.
P values for paired t-test of log values before and during treatment.
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Fig. 2. Mean intraarterial pressure before and during saralasin and captopril treatment. Values are the means SEM.
I I I I I
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Fig. 3. Regression equations of the relationships of the changes
of mean intraarterial pressure (AMAP) during saralasin (open
signs; full line) and of AMAP during captopril (closed signs; dot-
ted line) with control log PRA. The slopes of both regression
equations are similar; the intercepts differ significantly (P <
0.005). Circles represent essential hypertension; squares, renal
artery stenosis. Patients on chlorthalidone are indicated by an
asterisk.
= 20.9— 19.1 log PA!; r = —0.75; P < 0.01). Also for
these equations, the intercepts were significantly
different (P < 0.05) when captopril and saralasin
were compared.
The captopril-induced changes of MAP at the end
of the observation period were significantly related
Fig. 4. Relationship of AMAP during captopril with the con-
comittant changes of PA)! (log scale). Open symbols indicate low
sodium intake; closed signs, + chiorthalidone; circles, essential
hypertension; squares, renal artery stenosis.
to the drop in PAIl levels, but the correlation coeffi-
cient was low (LMAP = 4.28 — 18.43 log PAII; r =
—0.57; P < 0.05) (Fig. 4).
Discussion
Before discussing the results of the present study,
we must make some general remarks concerning
the outline. Several constraints were accepted in or-
der to complete the study of both drugs during a
single session, thus avoiding differences in experi-
mental circumstances and also repeated arterial
650 Fagard et al
140
130
a)
a)
-
120-
a)
Co
110
Co
a)
I .LL
0— — -O Saralasin
•—.—• Captopril
100 I I I I I I I I I I I I I I I
—10 0 +10 +20 +30 +40 +50 +60 +70
0* 0
0
10 25 50 100 250
0
II I I I I I I
SS
a)
0.
Co
a)
Co
C
Ca
Ca
+10 -
0-
—10 -
—20 -
—30 -
—40 —
—50 -
0
*
'. 0$ ..
.
*
'I-
0
*U
0*
N
0
.
U
S
S
0
a)
0.
a)
C
CO
a)
I
—10
—20 —
—30 —
—40
—50
0
' 0
.* S.
U
U
0
r = —0.57
P<0.05
0
Saralasin and cap topril in hypertension 651
punctures. An arterial catheter was felt desirable to
detect small differences in blood pressure response
and to allow arterial blood sampling; arterial blood
contains less metabolites of All that could interfere
with its measurement. (1) The administration of
drugs was always in the same chronologic order.
Because of the short half-life of saralasin, this drug
was given first, and 90 mm were allowed for its ef-
fects to dissipate; oral captopril, which has a termi-
nal phase plasma t72 of 4.5 hours, was always given
as a second drug. (2) The followup period for each
drug was rather short. Saralasin was infused for on-
ly 45 mm, but the fact that MAP reached a plateau
after 30 mm (Fig. 2) suggests that this time period
was adequate to fully oppose the acute vasocon-
strictor effects of All [15]. With 25mg of oral capto-
pril, pressure plateaued alter about 50 mm, so that a
75-mm followup period was considered adequate, in
accordance with other studies [8, 9]; also plasma
All was clearly suppressed, and probably at or
close to its lowest level after 75 mm (Fig. I). This
time-course could be in agreement with studies in
man where pressor responses to exogenously ad-
ministered Al were almost completely inhibited 15
to 30 mm after a single oral dose of 20 mg of capto-
pril [16]. Although the latter study suggested nearly
complete inhibition of the conversion of Alto All
by captopril, the circulating All of arterial blood
was only reduced to about one third of its initial val-
ue in the present study, and the activity of convert-
ing enzyme in the plasma to about half its control
level; also chronic treatment with higher doses of
captopril did not reduce the arterial All and con-
verting enzyme activity to lower levels (unpub-
lished data). There is no apparent explanation for
this discrepancy, but it is unlikely that the rise of Al
in response to the drug interfered with the All mea-
surements in view of the low cross-reactivity
(0.33%) of Al for the All antibody used. According
to these data, interference of Al in the All assay
starts above a plasma level of about 10 ng/ml,
whereas the highest measured Al level was 6.3 ng/
ml during both captopril and saralasin treatment.
For saralasin, with a 0.0025% cross-reactivity, a
plasma level of at least 1 pg/ml is required for inter-
ference in the radioimmunoassay of All. According
to Pettinger, Keeton, and Tanaka [17], who devel-
oped a direct radioimmunoassay of saralasin, such a
level is only obtained at an infusion rate of 20 g/kg/
mm, which is twice our rate.
The close relationship of the pressure response to
saralasin with the prevailing PRA (Fig. 3) and
plasma All levels is in agreement with previous ob-
servations [2—5]. In the present study, also the pres-
sure response to captopril was closely related to log
PRA, log PAl, and PAIl. The latter finding is divergent
from the early observations of Gavras et al [7], who
found no correlation between pretreatment PRA
and the decrement of mean blood pressure during
chronic treatment with captopril, although high-re-
nm patients, as a group, tended to have a better re-
sponse. The more recent data of Brunner et al [8]
and Case et al [9] are, however, in agreement with
our observations using PRA. In addition, we dem-
onstrated that the hypotensive effect of captopril
was greater than the effect of saralasin at any level
of PRA (Fig. 3), PA!, or PA!!, which has also been
shown for the i.v. administration of the converting
enzyme inhibitor SQ20881 [10]. Also, subtle dif-
ferences in the response of heart rate to the drugs
were observed. Saralasin, in agreement with pub-
lished reports [15, 18], did not affect heart rate ex-
cept for an initial decrease in response to the tran-
sient hypertensive effect, which has been related to
catecholamine release [15, 19]. Captopril, on the
contrary, produced a small but highly significant
tachycardia, already evident after 20 mm when the
hypotensive effect was similar to saralasin's, which
confirms previous observations in hypertensive
man [7] and normal rats [20]. Others, however, did
not observe increases in heart rate and/or cardiac
output in hypertensive man [21] and rats [20, 22],
and normal dogs [23]. The results in the literature
are thus contradictory, but our observations that
captopril does whereas saralasin does not induce
tachycardia in the same patients may point to dif-
ferent actions of the studied drugs.
The greater hypotensive effect of captopril when
compared to saralasin, with a different response of
heart rate, and the observation that the captopril-
induced changes of circulating All explained only
32% of the changes in pressure (Fig. 4), deserve
some comments, and several factors have to be
considered. (1) The variability of repeated All and
blood pressure measurements. (2) The possible in-
fluence of high Al levels and of exogenou sly admin-
istered saralasin in the in vitro All assay, which is,
however, unlikely in view of the low cross-reactiv-
ity of both peptides with the All antibody used, as
discussed. (3) Possible changes in All levels in oth-
er fluids and tissues, such as the arterial wall, which
may be badly reflected by the plasma All levels. (4)
The observations of Swartz et al [24], who demon-
strated that restoration of control blood pressure
during angiotensin converting enzyme inhibition
(SQ 20881) requires amounts of exogenous All lead-
ing to plasma All levels significantly above control,
which suggests that the hypotensive effect of con-
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verting enzyme inhibition is at least partly unrelated
to the inhibition of All formation. Such data are not
available for captopril. It has been claimed that cap-
topril has no direct effect on vascular smooth
muscle or on alpha- and beta-adrenoceptors, and
that it has no ganglion- or adrenergic-neurone
blocking activity [23, 25]. Because angiotensin con-
verting enzyme is identical to the kininase II that
degrades bradykinin [26], possible bradykinin accu-
mulation in response to converting enzyme inhibi-
tion has to be considered. Potentiation of bradyki-
nm-induced hypotension has been demonstrated [6,
25, 27], and blood kinin concentration was elevated
in some studies [24, 28, 29] whereas it was not in
another [30]. Because bradykinin-induced hypoten-
sion is accompanied by tachycardia [31], the in-
crease of heart rate is compatible with the kinin hy-
pothesis. (5) The fact that saralasin has been shown
to possess intrinsic agonistic angiotensin-like activi-
ty and to increase blood pressure in the presence of
a low circulating renin level, particularly in the so-
dium-loaded state; this effect is minimized by so-
dium-depletion [32—35]. It is possible that the ago-
fistic effect of saralasin contributed to the dif-
ference in blood pressure response to both drugs in
the present study, but is unlikely to explain the 11
mm Hg difference. Indeed, to better define the in-
trinsic pressor effect of saralasin in the conditions of
the present study, we infused saralasin in ten so-
dium-restricted patients in whom plasma All was
suppressed by captopril. The sustained increase of
pressure averaged 4.4 0.8 mm Hg (P < 0.001) (un-
published data).
The findings suggest that caution is required in
interpreting studies where the role of the renin-angi-
otensin system is studied by pharmacologic inter-
ference with angiotensin analogs or converting en-
zyme inhibition. Of course, if both drugs decrease
arterial pressure, be it to a different extent, that the
role of the system in the maintenance of pressure is
apparent but its exact quantitative contribution re-
mains unknown. If one drug does and the other drug
does not reduce arterial pressure, any interpretation
seems premature. There is still room for the devel-
opment of more specific inhibitors of the renin-angi-
otensin system.
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